Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study - 21/06/16
Abstract |
Background |
The association between immunosuppressive medication use and herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE) has not been clearly defined.
Objective |
We evaluated the risk of HZ in patients with SLE treated with different immunosuppressants.
Methods |
A nationwide population-based case-control study was conducted using the Taiwanese National Health Insurance Research Database. Cases (1555 patients with SLE who developed HZ) and controls (3049 age- and sex-matched patients with SLE but without HZ) were analyzed for use of various immunosuppressive medications in the preceding 3-month period, and dose-response relationships were determined. Logistic regression was performed to estimate the adjusted odds ratio for HZ development.
Results |
Medications associated with greater HZ risk in patients with SLE included oral corticosteroids, intravenous methylprednisolone, hydroxychloroquine, oral cyclophosphamide, intravenous cyclophosphamide, azathioprine, methotrexate, and mycophenolate mofetil. Combination immunosuppressive therapy was common in patients with SLE and was associated with greatly increased HZ risk. For oral corticosteroids and hydroxychloroquine, the risk of HZ was strongly dependent on the medication dose.
Limitations |
This study is retrospective in nature.
Conclusion |
Recent immunosuppressive medication use is associated with increased HZ risk in patients with SLE, particularly those receiving high-dose oral corticosteroids and multiagent immunosuppressive therapy.
Le texte complet de cet article est disponible en PDF.Key words : case-control study, epidemiology, herpes zoster, immunosuppressive medications, National Health Insurance Research Database, systemic corticosteroids, systemic lupus erythematosus
Abbreviations used : DDD, HZ, ICD-9, IV, NHIRD, OR, SLE
Plan
| Supported by grants from Kaohsiung Medical University Hospital (KMUH103-3T02, KMUH104-4T01, KMUH104-4R49). |
|
| Conflicts of interest: None declared. |
Vol 75 - N° 1
P. 49-58 - juillet 2016 Retour au numéro
Article précédent
- The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP)
- Elizabeth S. Robinson, Aimee S. Payne, Lisa Pappas-Taffer, Rui Feng, Victoria P. Werth
- Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years
- Andre Vadimovich Moyakine, Jorien Maria Kerstjens, Saskia Spillekom-van Koulil, Catharina Joanna Maria van der Vleuten
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?